7.4.3.2. immunotherapy/combination therapy. phase iii trial checkmate 214 (nct 02231749) showed superiority nivolumab ipilimumab sunitinib. primary endpoint population focused imdc intermediate- poor-risk population combination demonstrated os benefit (hr: 0.63, 95% ci: 0.44-0.89) led regulatory approval paradigm shift treatment mrcc . results checkmate 214 established combination ipilimumab nivolumab associated higher response rates (rr) (39% itt population), complete rr (8% itt population [central radiology review]) duration response compared sunitinib. progression-free survival achieve pre-defined endpoint. exploratory analysis os data pd-l1-positive population 0.45 (95% ci: 0.29-0.41). recent update 60-month data shows ongoing benefits immune combination independently assessed complete response rates 11% hr os imdc intermediate- poor-risk group 0.68 (0.58-0.81) . however, complete response rate consistent across trials combination (the cosmic313 study showed complete response rates 3% ). checkmate 214 60-months os probability 43% ipilimumab plus nivolumab vs. 31% sunitinib, respectively . update imdc good-risk group continue perform better sunitinib although effect occurs due late overlap kaplan-meier curves (hr os: 0.94 [95% ci: 0.65-1.37]) . nivolumab plus ipilimumab associated 46% grade iii-iv toxicity 1.5% treatment-related deaths. therefore administered centres experience immune combination therapy appropriate supportive care within context multidisciplinary team (le: 4). pd-l1 biomarker currently used select patients therapy. frequency steroid use generated controversy analysis, well real world data, required. reasons panel continues recommend ipilimumab nivolumab intermediate- poor-risk population. keynote-426 trial (nct02853331 reported results combination axitinib plus pembrolizumab vs. sunitinib 861 treatment-naive cc-mrcc patients . overall survival pfs assessed central independent review itt population co-primary endpoints. response rates assessment pd-l1-positive patient population secondary endpoints. minimum follow-up 35.6 months (median 42.8 months) trial demonstrated ongoing os benefit axitinib plus pembrolizumab itt population (hr: 0.73, 95% ci: 0.60-0.88, p < 0.001). median os axitinib plus pembrolizumab 45.7 months (95% ci: 43.6 - nr) vs. 40.1 month (95% ci: 34.3 - 44.2) sunitinib pfs benefit (hr: 0.68, 95% ci: 0.58-0.80, p < 0.0001) shown across imdc subgroups pfs, os similar axitinib plus pembrolizumab vs. sunitinib favourable subgroup os benefit imdc intermediate- poor-risk groups. complete response rate independent review 10% pembrolizumab plus axitinib arm 4% sunitinib arm . extended median follow-up 67 months median os 47.2 months (43.6-54.8) vs. 40.8 months (34.3-47.5; hr 0.84 95%ci: 0.71-0.99)) sunitib, median pfs 15.7 (13.6-20.2) vs. 11.1 (8.9-12.5) hr 0.69 (95% ci: 0.59-0.81) orr 60.6% (cr 11.6%) vs. 39.6% (cr 4.0%) . treatment-related adverse events (≥ grade iii) occurred 63% patients receiving axitinib pembrolizumab vs. 58% patients receiving sunitinib. treatment- related deaths occurred approximately 1% arms . phase iii checkmate 9er trial randomised 651 patients nivolumab plus cabozantinib (n = 323) vs. sunitinib (n = 328) treatment-naive cc-mrcc patients . primary endpoint pfs assessed central independent review itt population significantly prolonged nivolumab plus cabozantinib (16.6 months) vs. sunitinib (8.3 months, hr: 0.51, 95% ci: 0.41-0.64, p < 0.0001). nivolumab/cabozantinib combination also demonstrated significant os benefit secondary endpoint compared sunitinib (hr: 0.60, ci: 0.40-0.89, p = 0.0010) median follow-up 18.1 months initial report . independently assessed orr 55.7% vs. 27.1% complete response rate 8% nivolumab plus cabozantinib vs. 4.6% sunitinib. efficacy observed independent imdc group pd-l1 status. treatment-related adverse events (> grade iii) occurred 61% patients receiving cabozantinib nivolumab vs. 51% patients receiving sunitinib. treatment-related deaths occurred one patient nivolumab/cabozantinib arm two patients sunitinib arm. extended follow-up median 44 months median os 49.5 months (40.3-not estimable) nivolumab plus cabozantinib patients vs. 35.5 months (29.2-42.3) sunitinib treated patients (hr: 0.70 [95% ci: 0.56-0.87, p = 0.0043). updated median pfs 16.6 months (12.8-19.5) vs. 8.4 months (7.0-9.7; hr 0.59 [95% ci: 0.49-0.71], p < 0·0001 . randomised phase iii trial clear (lenvatinib/everolimus lenvatinib/pembrolizumab vs. sunitinib alone treatment advanced rcc) published . clear randomised total 1,069 patients (in 1:1:1 ratio) lenvatinib plus pembrolizumab (n = 355) vs. lenvatinib plus everolimus (n = 357) vs. sunitinib (n = 357). trial reached primary endpoint independently assessed pfs median 23.9 vs. 9.2 months, lenvatinib plus pembrolizumab vs. sunitinib, respectively (hr: 0.39, 95% ci: 0.32-0.49, p < 0.001). overall survival significantly improved lenvatinib plus pembrolizumab vs. sunitinib (hr: 0.66, 95% ci: 0.49-0.88, p = 0.005). objective response lenvatinib plus pembrolizumab 71% 16% patients complete remission. final analyis median follow-up 49.8 months median os 53.7 months (48.7-not estimable) lenvatinib plus pembrolizumab vs. 54.3 (40.9-not estimable; hr 0.79 95% ci: 0.63-0.99) sunitinib . efficacy observed across imdc risk groups, independently pd-l1 status. treatment-related adverse events (> grade iii) lenvatinib plus pembrolizumab 72%. treatment-related death occurred four patients lenvatinib plus pembrolizumab arm one patient sunitinib arm. javelin trial investigated 886 patients phase iii rct avelumab plus axitinib vs. sunitinib . trial met one co-primary endpoints (pfs pd-l1-positive population first interim analysis [median follow 11.5 months]). hazard ratios pfs os itt population 0.69 (95% ci: 0.56-0.84) 0.78 (95% ci: 0.55-1.08), respectively, missing significant os improvement also longer follow-up third interim analyis median follow-up 34.1 months . applies atezolizumab/bevacizumab combination (immotion151) also achieved pfs advantage sunitinib pd-l1-positive population interim analysis itt (hr: 0.74, 95% ci: 0.57-0.96), shown significant os advantage final analysis (hr: 0.91 [95% ci: 0.76-1.08], p = 0.27) . therefore, combinations cannot currently recommended. imdc favourable patients treatment axitinib+pembrolizumab (keynote-426), cabozantinib+nivolumab (checkmate-9er) lenvatinib+pembrolizumab (clear) improved pfs objective response rate, os . given long-term follow-up os improvement respective tki+io combination vs sunitinib, tki monotherapy becomes standard care additiional choice imdc favourable patients. although sunitinib tki monotherapy used theses trials, pazopanib valid alternative based non-inferiority data phase iii trial comparz . cosmic-313 trial first rct evaluate triple combination cabozantinib (40 mg) plus nivolumab plus ipilimumab vs. nivolumab plus ipilimumab, current standard care, 855 patients imdc intermediate- poor-risk . primary endpoint pfs improvement, measured pfs itt 550 patient met 249 events occurred hr 0.73 (95% ci: 0.57-0.94, p = 0.013) favouring triplet therapy. median pfs reached (14.0-ne) vs. 11.3 months (7.7-18.2) control arm median follow-up 20.2 months. overall survival yet reported. objective response 43% vs. 36% triplet vs. control arm complete response rate 3% arms. treatment-related adverse events (> grade iii) cabozantinib plus nivolumab plus ipilimumab 73% vs. 41% nivolumab plus ipilimumab control arm. use high-dose steroids (> = 40 mg prednisolone equivalent) 58% (triplet) vs. 35%. (control). treatment discontinuation rate agent high triplet arm (45%) compared doublet (24%), whilst discontinuation treatments due adverse events 12% vs. 5% control arm. although primary endpoint pfs met, objective response rates triplet combination modest known tki + io doublets. treatment-related adverse events high high rate treatment discontinuation. os rate currently unknown, additional benefit triplet therapy compared standard immune-based doublet therapy still uncertain. table 7.4: first line immune checkpoint inhibitor combination trials clear-cell rcc cross trial comparison recommended occur caution studynexperimental armprimary endpointrisk groupspfs (mo)median (95% ci)hros (mo)median (95% ci)hrkeynote-426nct02853331median follow-up 67 months[502,568-570]861pembro 200 mg. iv q3w plus axi 5 mg. po bidvs.sun 50 mg poqd 4/2 wk.pfs os itt bicrimdcfav 31%imd 56%poor 13%mskccnot determined(itt)pembro + axi: 15.7 (13.6-20.2)sun: 11.1 (8.9-12.5)hr: 0.69 (95% ci: 0.59-0.81)p < 0.0001(itt)pembro + axi: 47.2. (43.6-54.8)sun: 40.8 (34.3-47.5)hr:, 0.84 (95% ci: 0.71[0.99)p = 0.001javelin 101nct02684006median follow-up 34.1 months886ave 10 mg/kg iv q2w plus axi, 5 mg po bidvs.sun 50 mg po qd 4/2 wk.pfs pd-l1+ population os itt bicrimdcfav 22%imd 62%poor 16%mskccfav 23%imd 66%poor 12%(pd-l1+)ave + axi: 13.9 (11.0-17.8)sun: 8.2 (6.9-9.4)hr: 0.67 (95% ci: 0.57-0.79)p < 0.0001(pd-l1+)ave+axi: nr (40.0-nr)sun: 36.2 (30.0-ne)hr, 0.81 (95% ci: 0.62-1.04)p = 0.0498immotion151nct02420821median follow-up 24 months 915atezo 1200 mg fixed dose iv plus bev 15 mg/kg iv days 1 22 42-day cyclevs.sun 50 mgpo qd 4/2 wk.pfs pd-l1+ population os itt irimdcnot determinedmskccfav 20%imd 69%poor 12%(pd-l1+)atezo + bev: 11.2 (8.9-15.0)sun: 7.7 (6.8-9.7)hr: 0.74 (95% ci: 0.57-0.96)p = 0.0217(itt)atezo + bev: 36.1 (31.5-42.3)sun: 35.3 (28.6-42.1ne)hr: 0.91 (95% ci: 0.76-1.08)p = 0.27checkmate214nct02231749median follow-up 60 months 1096nivo 3 mg/kg plus ipilimumab 1 mg/kg iv q3w 4 doses nivolumab 3 mg/kg iv q2wvs.sun 50 mgpo qd 4/2 wk.pfs os imdc inter-mediateand poorrisk populationby bicrimdcfav 23%imd 61%poor 17%mskccnot determined(imdc imd/poor)nivo + ipi: 11.6(8.4-16.5)sun: 8.3 (7.0-10.4)hr: 0.73 (95% ci: 0.61-0.87)(imdc imd/poor)nivo + ipi: 47.0 (35.4-57.4)sun: 26.6(22.1-33.5)hr: 0.68 (0.58-0.81)p = < 0.0001checkmate9ernct03141177median follow-up 44 months651nivo 240 mg. fixed dose iv every 2 wk. plus cabo 40 mg po daily vs.sun 50 mg po qd 4/2 wk.pfs itt bicrimdcfav 22%imd 58%poor 20%mskccnot determined(itt)nivo+cabo: 16.6 (12.8-19.5)sun: 8.4 (7.0-9.7)hr: 0.59 (95% ci: 0.49-0.71)p <0.0001(itt)nivo+cabo: 49.5 (40.3-ne)sun: 35.5 (29.2-42.3)hr: 0.70 (98.9% ci: 0.56-0.87)p = 0.0034clearnct02811861median follow-up 49.8 months 712pembro 200 mg iv q3w plus len 20 mg po qdvs.sun 50 mg po qd 4/2 wk.pfs itt bircimdcfav 31%imd 59%poor 9%ne 1%mskccfav 27%imd 64%poor 9%(itt)pembro+len: 23.9 (20.8-27.7)sun: 9.2 (6.0-11.0)hr: 0.47 (95% ci: 0.38-0.57) p > 0.001(itt)pembro+len: 53.7 (48.7-ne)sun: 54.3 (40.9-ne)hr: 0.79 (95% ci: 0.63-0.99)p = 0.005cosmic-313median follow-up 20.2 months 855nivo 3 mg/kg plus ipi 1 mg/kg iv q3w 4 doses nivo 3 mg/kg iv q2w + cabo 40mg po qdvs. nivo 3 mg/kg plus ipi 1 mg/kg iv q3w 4 doses nivo 3 mg/kg iv q2wpfs thepittpopulation (first 550 pts. rando-mised)imdcimd 75%poor 25%(pitt)nivo+ipi+cabo:nr (14.0-ne)nivo+ipi: 11.3 (7.7-18.2)hr: 0.73 (95% ci: 0.57-0.94) p = 0.013nr atezo = atezolizumab; ave = avelumab; axi = axitinib; bev = bevacizumab; bicr = blinded independent central review; bid = twice day; cabo = cabozantinib; ci = confidence interval; fav = favourable; hr = hazard ratio;ipi = ipilimumab; imd = intermediate; imdc = metastatic renal cancer database consortium; ir = investigator review; itt = intention-to-treat; iv = intravenous; len = lenvatinib; mo = months; mskcc = memorial sloan kettering cancer center; ne = non-estimable; nr = reached; nivo = nivolumab; os = overall survival;pembro = pembrolizumab; pfs = profession-free survival; pitt = pfs intention-to-treat; po = mouth;pts = patients; qd = day; q2w = every 2 weeks; q3w = every 3 weeks; sun = sunitinib; wk = weeks. patients stop nivolumab plus ipilimumab toxicity require expert guidance support multidisciplinary team re-challenge occur (le: 1). patients receive full four doses ipilimumab due toxicity continue single-agent nivolumab, safe feasible (le: 4). treatment past progression nivolumab plus ipilimumab justified requires close scrutiny support expert multidisciplinary team (le: 1). patients stop tki io due immune-related toxicity receive single-agent tki adverse events resolved (le: 1). adverse event management, including transaminitis diarrhoea, require particular attention agents may causative. expert advice sought re-challenge icis significant toxicity (le: 4). treatment past progression axitinib plus pembrolizumab nivolumab plus cabozantinib requires careful consideration biologically distinct treatment past progression ipilimumab nivolumab. based panel consensus, nivolumab plus ipilimumab, pembrolizumab plus axitinib nivolumab plus cabozantinib lenvatinib plus pembrolizumab administered centres experience immune combination therapy appropriate supportive care within context multidisciplinary team (le: 4).